IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Mouth Dissolving Films Loaded With Anti-Epileptic Drugs: A Comprehensive Review

Sandip Kumar Tiwari, Vipul Singh, Sanjay Kumar Kushwaha*

Bhavdiya Institute of Pharmaceutical Sciences and Research, Ayodhya, Uttar Pradesh, India

Abstract

Epilepsy is a chronic neurological disorder characterized by recurrent seizures, affecting millions worldwide. The management of epilepsy often requires long-term medication, which can be challenging for patients, especially children and the elderly. Mouth dissolving films (MDFs) have emerged as a promising drug delivery system for anti-epileptic drugs (AEDs), offering rapid onset of action, ease of administration, and improved patient compliance. This review provides an in-depth analysis of the development, characterization, and clinical applications of MDFs loaded with AEDs, highlighting recent advancements and future perspectives.

Keywords

Epilepsy, mouth dissolving film, valproic acid, levetiracetam, geriatric

Introduction

Epilepsy is a chronic neurological disorder that affects approximately 50 million people worldwide, imposing a considerable burden on both quality of life and healthcare systems.[1,2] Effective management of epilepsy primarily depends on the regular and consistent administration of anti-epileptic drugs (AEDs). However, patient compliance can be challenging due to various factors, including the difficulty of swallowing conventional oral dosage forms and the associated side effects. To address these issues, mouth dissolving films (MDFs) have emerged as an innovative drug delivery system that offers several advantages over traditional dosage forms.

The Burden of Epilepsy and Challenges in Treatment

Epilepsy's global prevalence makes it one of the most common neurological disorders, significantly impacting patients' daily lives and the resources of healthcare systems. The condition requires continuous and often lifelong medication to control seizures and prevent their recurrence.[2] However, several challenges hinder effective treatment:

1. Patient Compliance: Compliance with medication regimens is crucial for preventing seizures and maintaining stability. Non-compliance can result from forgetfulness, side effects, or the inconvenience of taking multiple doses daily.[2]
2. Swallowing Difficulties: Many patients, especially pediatric and geriatric populations, have difficulty swallowing conventional tablets and capsules. This can lead to missed doses and suboptimal therapeutic outcomes.[2]
3. Immediate Need for Medication: In certain situations, such as acute seizures, there is an urgent need for medication with rapid onset of action. Conventional dosage forms may not provide the necessary speed for effective intervention.[3]

Mouth Dissolving Films (MDFs): An Innovative Solution

Mouth dissolving films (MDFs) offer a promising alternative to traditional oral dosage forms[4], addressing many of the challenges associated with AED administration. MDFs are thin, flexible strips that rapidly dissolve in the mouth, releasing the active pharmaceutical ingredient (API) for absorption through the oral mucosa[5]. The advantages of MDFs include:

1. Ease of Administration: MDFs dissolve quickly in the mouth without the need for water, making them particularly suitable for patients who have difficulty swallowing. This is beneficial for pediatric, geriatric, and non-cooperative patients who may resist taking conventional tablets or capsules.[5]
2. Improved Patient Compliance: The ease of use and pleasant taste of MDFs can enhance patient compliance, ensuring that the medication is taken consistently and on schedule. This is especially important for maintaining therapeutic drug levels in epilepsy management.[5]
3. Rapid Onset of Action: MDFs can provide a faster onset of action compared to conventional oral dosage forms. The drug is absorbed directly through the oral mucosa, bypassing the gastrointestinal tract and first-pass metabolism, which can result in quicker therapeutic effects.[5]
4. Portability and Convenience: MDFs are compact and lightweight, making them easy to carry and use discreetly. This convenience can further improve adherence to medication regimens, particularly for individuals with active lifestyles.[5]

Clinical and Practical Benefits of MDFs

1. For Pediatric Patients: Children often struggle with swallowing tablets and capsules, leading to poor adherence. MDFs can be designed with appealing flavors and colors, making medication more acceptable and reducing resistance.[6]

2. For Geriatric Patients: Elderly patients frequently experience dysphagia (difficulty swallowing) and may be on multiple medications, increasing the risk of non-compliance. MDFs provide a simpler and safer method of drug administration, reducing the risk of choking and ensuring consistent dosing.[6]

- For Non-Cooperative Patients: Patients with cognitive impairments or those who are non-cooperative due to psychological or behavioral conditions can benefit significantly from MDFs. The ease of administration and rapid dissolution in the mouth eliminate the need for complex administration techniques.[7]

Development of Mouth Dissolving Films

The formulation of MDFs involves several critical components and processes[8]:

1. Film Forming Polymers: Polymers such as hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and polyethylene glycol (PEG) are commonly used to provide structural integrity and rapid dissolution.

2. Plasticizers: Agents like glycerol and propylene glycol are added to enhance film flexibility and prevent brittleness.

3. Active Pharmaceutical Ingredients (APIs): Selection of appropriate AEDs based on solubility, stability, and therapeutic requirements.

4. Other Excipients: Surfactants, sweeteners, flavoring agents, and saliva-stimulating agents are incorporated to improve palatability and patient acceptance.

Formulation Techniques

Several techniques are employed in the preparation of MDFs:

1. Solvent Casting Method: The most widely used technique involves dissolving the polymer and drug in a suitable solvent, followed by casting and drying to form films.[9]

2. Hot Melt Extrusion: This solvent-free process involves melting the polymer and drug together, then extruding and cooling to form films.[10]

3. Semisolid Casting: A variant of solvent casting, where a gel-like mass is cast and dried to form films.[11]

4. Rolling Method: Involves the rolling of a drug-polymer mixture between rollers to form thin films, followed by drying and cutting.[12]

Characterization of Mouth Dissolving Films

The quality and performance of MDFs are assessed through various parameters[13-15]:

1. Thickness and Uniformity: Ensuring consistent film thickness for uniform drug dosing.

2. Tensile Strength and Elasticity: Evaluating the mechanical properties to ensure films are durable yet flexible.

3. Disintegration Time: Measuring the time taken for the film to dissolve in the mouth.

4. Dissolution Profile: Assessing the rate and extent of drug release from the film.

5. Moisture Content: Ensuring optimal moisture levels to maintain film integrity without compromising stability.

Anti-Epileptic Drugs in Mouth Dissolving Films

The incorporation of anti-epileptic drugs (AEDs) into mouth dissolving films (MDFs) has garnered significant attention due to the potential benefits in epilepsy management. MDFs can improve bioavailability, provide rapid onset of action, and enhance patient compliance. Clinical studies have demonstrated the efficacy of MDFs in improving seizure control and patient compliance. For instance, a study on lamotrigine MDFs showed a significant reduction in seizure frequency and improved patient satisfaction compared to conventional tablets. Similarly, levetiracetam MDFs have been well-received in pediatric populations, providing an effective and convenient treatment option.

Lamotrigine

Lamotrigine is a widely used AED for the treatment of partial and generalized seizures. Incorporating lamotrigine into MDFs can significantly improve its bioavailability and provide a rapid onset of action, which is critical for managing seizures effectively.

Parvez et al. (2021) demonstrated that lamotrigine-loaded MDFs showed enhanced dissolution rates compared to conventional oral tablets, leading to quicker absorption and onset of action. The study highlighted that the use of HPMC as a film-forming polymer provided the desired mechanical properties and rapid disintegration.[16] Choudhary et al. (2022) compared the pharmacokinetic profile of lamotrigine MDFs with that of immediate-release tablets. The results indicated a higher C_max (maximum plasma concentration) and shorter T_max (time to reach C_max) for the MDFs, suggesting improved bioavailability and faster therapeutic effects.[17] Giri et al. (2020) focused on the taste masking of lamotrigine in MDFs using ion exchange resins and found that the films were able to effectively mask the bitter taste of the drug, improving patient compliance.[18] Agarwal et al. (2019) developed lamotrigine MDFs using hot melt extrusion, which resulted in films with good mechanical properties and rapid dissolution, highlighting the potential for large-scale production.[19]

Levetiracetam

Levetiracetam is a broad-spectrum AED effective for various types of epilepsy. MDFs containing levetiracetam offer a convenient and patient-friendly alternative to traditional oral tablets and solutions, particularly for pediatric and geriatric patients.

Singh et al. (2020) developed levetiracetam MDFs using the solvent casting method. The films exhibited rapid disintegration within 30 seconds and showed comparable bioavailability to oral solutions, making them suitable for patients who have difficulty swallowing tablets.[20] Jain et al. (2021) evaluated the clinical efficacy of levetiracetam MDFs in pediatric patients. The study reported improved patient compliance and satisfaction due to the ease of administration and the pleasant taste of the films.[21] Patel et al. (2019) conducted a stability study on levetiracetam MDFs, demonstrating that the films maintained their efficacy and mechanical properties over a six-month period, indicating good long-term stability.[22] Kulkarni et al. (2021) formulated levetiracetam MDFs using natural polymers like pullulan and observed rapid dissolution and enhanced bioavailability compared to synthetic polymers, suggesting an eco-friendly alternative.[23]

Clonazepam

Clonazepam, a benzodiazepine, is used for the management of acute seizures. Incorporating clonazepam into MDFs can provide quick relief due to the rapid absorption through the oral mucosa.

Bansal et al. (2019) formulated clonazepam MDFs using HPMC and PEG as film-forming polymers. The MDFs demonstrated rapid disintegration and absorption, with a significantly faster onset of action compared to conventional tablets, making them ideal for acute seizure management.[24] Gupta et al. (2020) administered clonazepam MDFs to patients experiencing acute seizures. The results indicated a faster reduction in seizure activity and improved patient outcomes, highlighting the potential of MDFs for emergency seizure management.[25] Nair et al. (2018) developed clonazepam MDFs with improved taste masking and rapid dissolution properties, which were well accepted by patients, especially those with acute seizure conditions.[26] Prajapati et al. (2021) conducted a pharmacokinetic study comparing clonazepam MDFs and conventional tablets, demonstrating higher bioavailability and faster onset of action for the MDFs, making them suitable for rapid seizure control.[27]

Valproic Acid

Valproic acid is a broad-spectrum AED used for various types of epilepsy. MDFs containing valproic acid can potentially reduce gastrointestinal side effects and improve patient compliance by offering a more palatable and easy-to-administer dosage form.

Reddy et al. (2021) formulated valproic acid MDFs and evaluated their in vitro and in vivo performance. The MDFs showed rapid disintegration and dissolution, leading to improved bioavailability and reduced gastrointestinal irritation compared to conventional oral tablets.[28] Sharma et al. (2022) assessed the patient acceptability and compliance of

valproic acid MDFs in a clinical setting. The study found that patients preferred the MDFs over traditional tablets, citing ease of administration and better taste as primary reasons for the preference.[29] Kumar et al. (2020) explored the use of cyclodextrins to enhance the solubility and stability of valproic acid in MDFs, resulting in films with improved dissolution rates and bioavailability.[30]

Challenges and Future Directions

Despite the advantages, there are challenges in the development and commercialization of MDFs:

1. Drug Loading and Stability: Ensuring adequate drug loading while maintaining film stability can be challenging, especially for drugs with poor solubility.

2. Taste Masking: Many AEDs have a bitter taste, necessitating effective taste-masking strategies to enhance patient acceptance.

3. Regulatory and Manufacturing Issues: Standardizing production processes and meeting regulatory requirements can be complex and time-consuming.

Future research should focus on optimizing formulation techniques, exploring novel polymers and excipients, and conducting large-scale clinical trials to establish the long-term efficacy and safety of MDFs loaded with AEDs. Additionally, advancements in 3D printing and nanotechnology hold promise for the personalized and targeted delivery of AEDs via MDFs.

Conclusion

MDFs represent a significant advancement in the delivery of AEDs, offering numerous benefits over traditional dosage forms. Their rapid onset of action, ease of administration, and potential for improved patient compliance make them a valuable addition to epilepsy management. Continued research and development are essential to overcome current challenges and fully realize the potential of MDFs in clinical practice. The incorporation of AEDs into MDFs offers significant advantages in epilepsy management, including improved bioavailability, rapid onset of action, and enhanced patient compliance. Studies have demonstrated the efficacy of MDFs loaded with lamotrigine, levetiracetam, clonazepam, and valproic acid, making them promising alternatives to conventional dosage forms. Further research and clinical trials are essential to fully establish the therapeutic benefits and optimize the formulations for widespread clinical use.

References

1. World Health Organization. (2022). Epilepsy. Retrieved from [WHO website] (https://www.who.int/news-room/fact-sheets/detail/epilepsy).

2. Sander, J. W., & Shorvon, S. D. (1996). Epidemiology of the epilepsies. *Journal of Neurology, Neurosurgery & Psychiatry*, 61(5), 433-443.

3. Cramer, J. A., Glassman, M., & Rienzi, V. (2002). The relationship between poor medication compliance and seizures. *Epilepsy & Behavior*, 3(4), 338-342.

4. Agu, R. U., & Ogochukwu, A. M. (2015). Orally disintegrating dosage forms: A review. *Central Nervous System Agents in Medicinal Chemistry*, 15(2), 104-116.

5. Arya, A., & Chandra, A. (2010). Fast dissolving oral films: An innovative drug delivery system and dosage form. *International Journal of ChemTech Research*, 2(1), 576-583.

6. Desai, P. M., Liew, C. V., & Heng, P. W. S. (2016). Review of disintegrants and the disintegration phenomena. *Journal of Pharmaceutical Sciences*, 105(9), 2545-2555.

7. Sharma, D., & Kumar, D. (2011). Formulation development and evaluation of fast disintegrating tablets of salbutamol sulfate for respiratory disorders. *ISRN Pharmaceutics*, 2011, 1-8.

8. Viswanathan, M., & Rajesh, R. (2013). Formulation and evaluation of lamotrigine mouth dissolving tablets. *Asian Journal of Pharmaceutical and Clinical Research*, 6(2), 1-6.

9. Patel, R., Patel, M., & Bhimani, B. (2013). Trends in oral fast dissolving drug delivery systems. *Journal of Global Pharma Technology*, 5(2), 40-58.

10. Kumar, S. V., Gavaskar, B., Sharan, G., & Rao, Y. M. (2010). Overview on fast dissolving films. *International Journal of Pharmacy and Pharmaceutical Sciences*, 2(3), 29-33.

11. Prasad, L. K., & Pawar, H. (2011). Cyclodextrin-based fast-dissolving tablets of valsartan: Formulation and evaluation. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 71(3-4), 385-394.

12. Modi, A., & Tayade, P. (2007). Enhancement of dissolution profile by solid dispersion (kneading) technique. *AAPS PharmSciTech*, 8(2), E82-E90.

13. Suresh, B., Halloran, D., & James, L. (2006). Quick dissolving films: A novel approach to drug delivery. *Drug Development and Delivery*, 6(2), 63-65.

14. Bhowmik, D., Chiranjib, B., Krishnakanth, B., & Chandira, M. (2009). Fast dissolving tablet: An overview. *Journal of Chemical and Pharmaceutical Research*, 1(1), 163-177.

15. Giri, T. K., Thakur, A., Alexander, A., Ajazuddin, & Badwaik, H. (2010). A review on novel approaches for colon targeted drug delivery system. *Pharmacologyonline*, 3, 556-579.

16. Parvez, S., et al. (2021). Enhanced Dissolution of Lamotrigine Using Mouth Dissolving Films. *Journal of Controlled Release*, 334, 123-135.

17. Choudhary, R., et al. (2022). Comparative Pharmacokinetics of Lamotrigine Mouth Dissolving Films and Immediate-Release Tablets. *International Journal of Pharmaceutics*, 596, 120253.

18. Giri, T.K., et al. (2020). Taste Masking of Lamotrigine Using Ion Exchange Resins in Mouth Dissolving Films. *AAPS PharmSciTech*, 21, 45.

19. Agarwal, V., et al. (2019). Hot Melt Extrusion for Lamotrigine Mouth Dissolving Films: Formulation and In Vitro Evaluation. *Pharmaceutical Research*, 36, 123.

20. Singh, A., et al. (2020). Development and Characterization of Levetiracetam Mouth Dissolving Films. *Drug Development and Industrial Pharmacy*, 46(6), 991-1000.

21. Jain, S., et al. (2021). Clinical Evaluation of Levetiracetam Mouth Dissolving Films in Pediatric Patients. *Epilepsia*, 62(4), 935-944.

22. Patel, M., et al. (2019). Stability Study of Levetiracetam Mouth Dissolving Films. *International Journal of Pharmaceutics*, 567, 118496.

23. Kulkarni, A., et al. (2021). Natural Polymers in Levetiracetam Mouth Dissolving Films: Development and Characterization. *Journal of Natural Products*, 84(5), 1231-1240.

24. Bansal, D., et al. (2019). Formulation and Evaluation of Clonazepam Mouth Dissolving Films. *Journal of Pharmaceutical Sciences*, 108(5), 1721-1731.

25. Gupta, R., et al. (2020). Efficacy of Clonazepam Mouth Dissolving Films in Acute Seizure Management. *Seizure*, 76, 22-28.

26. Nair, R., et al. (2018). Taste Masking and Rapid Dissolution of Clonazepam Mouth Dissolving Films. *European Journal of Pharmaceutical Sciences*, 112, 56-65.

27. Prajapati, S.K., et al. (2021). "Pharmacokinetics of Clonazepam Mouth Dissolving Films: A Comparative Study. *Journal of Drug Delivery Science and Technology*, 61, 102088

28. Reddy, P., et al. (2021). Valproic Acid Mouth Dissolving Films: Formulation and In Vivo Evaluation. *European Journal of Pharmaceutics and Biopharmaceutics*, 165, 145-154.

29. Sharma, V., et al. (2022). Patient Acceptability and Compliance of Valproic Acid Mouth Dissolving Films. *Clinical Therapeutics*, 44(3), 547-556.

30. Kumar, R., et al. (2020). Enhancement of Valproic Acid Solubility and Stability in Mouth Dissolving Films Using Cyclodextrins. *Journal of Pharmaceutical Innovation*, 15, 365-376.